Search results for Monalizumab
Monalizumab Biosimilar – Anti-KLRC1, NKG2A, CD159a, CD94 mAb – Research Grade, ProteoGenix, PX-TA1392
Description of Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade General information on Anti-KLRC1/NKG2A/CD159a/CD94[Homo sapiens] (Monalizumab) Monoclonal Antibody Monalizumab has been investigated for the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
Host
Reactivity
Applications
Conjugation
Monalizumab, Abbexa, abx831351
Monalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KLRC1/NKG2A/CD159a/CD94, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Monalizumab Biosimilar - Research Grade, ichor.bio, ICH5017
Detects human CD159a. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Monalizumab.
Host
CHO cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.